Flurandrenolide and Osimertinib Mesylate

• Generic Name: flurandrenolide topical
• Dosage Forms: n.a.
• Other Brand Names: Cordran, Cordran SP, Cordran Tape, Nolix

Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Generally most effective in acute or chronic dermatoses (e.g., seborrheic or atopic dermatitis, localized neurodermatitis, anogenital pruritus, psoriasis, late phase of allergic contact dermatitis, inflammatory phase of xerosis).

Topical therapy generally preferred over systemic therapy; fewer associated adverse systemic effects.

Topical therapy generally only controls manifestations of dermatoses; eliminate cause if possible.

Topical efficacy may be increased by using a higher concentration or occlusive dressing therapy. (See Administration with Occlusive Dressing under Dosage and Administration.)

Response may vary from one topical corticosteroid preparation to another.

Anti-inflammatory activity may vary considerably depending on the vehicle, drug concentration, site of application, disease, and individual patient.

Flurandrenolide 0.05% ointment is considered to have high-range potency.

Flurandrenolide 0.05% cream is considered to have medium-range potency.

• Generic Name: osimertinib
• Dosage Forms: n.a.
• Other Brand Names: Tagrisso

First-line treatment of metastatic NSCLC in patients with epidermal growth factor receptor (EGFR) exon 19 deletions (del19) or exon 21 (L858R) substitution mutations (as detected by an FDA-approved diagnostic test).

Treatment of metastatic NSCLC in patients with EGFR T790M mutation (as detected by an FDA-approved diagnostic test) who have experienced disease progression during or after EGFR tyrosine kinase inhibitor therapy.

Designated an orphan drug by FDA for treatment of EGFR mutation-positive NSCLC.